A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

BackgroundCompared with the standard of care with sunitinib, avelumab plus axitinib can increase progression-free survival in the first-line of advanced renal cell carcinoma (RCC), but the economic effect of the treatment is unknown. The purpose of the research was to evaluate the cost-effectiveness...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Peiyao Lu (Yazar), Weiting Liang (Yazar), Jiahao Li (Yazar), Yanming Hong (Yazar), Zhuojia Chen (Yazar), Tao Liu (Yazar), Pei Dong (Yazar), Hongbing Huang (Yazar), Tiantian Zhang (Yazar), Jie Jiang (Yazar)
Materyal Türü: Kitap
Baskı/Yayın Bilgisi: Frontiers Media S.A., 2020-05-01T00:00:00Z.
Konular:
Online Erişim:Connect to this object online.
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Internet

Connect to this object online.

3rd Floor Main Library

Detaylı Erişim Bilgileri 3rd Floor Main Library
Yer Numarası: A1234.567
Kopya Bilgisi 1 Kütüphanede